Network Version
ML314 Data Sheet
| Product Name: | ML314 |
 |
|---|---|---|
| CAS No.: | 1448895-09-7 | |
| Cat. No.: | HY-16639 | |
| MWt: | 420.5 | |
| Formula: | C24H28N4O3 | |
| Purity : | >98% | |
| Solubility: | ||
| Mechanisms: | Target: Endocrinology Neurological Disease | |
| Biological Activity: | ||
|
ML314 is a potent, BBB-penetrant and β-arrestin biased molecule agonist of NTR1 (EC50 = 1.9 μM). ML314 shows good selectivity against NTR2 and GPR35, but does not stimulate Ca2+ mobilization. ML314 can attenuate amphetamine-like hyperlocomotion in dopamine transporter knockout mice. ML314 attenuates methamphetamine-associated hyperlocomotion and potentiates the psychostimulant inhibitory effects of a ghrelin antagonist in wild type mouse model. ML314 also acts as an allosteric enhancer of endogenous neurotensin. ML314 antagonizes G protein signaling. ML314 can be studied in research for methamphetamine abuse conditions[1][2].
In Vitro:ML314 (10 μM) induces aggregation of β-arrestin in NTR1β-arrestin2/GFP containing U2OS cells[2]. ML314 (10 μM, 10 min) antagonizes G protein signaling in HEK293 cells expressing NTR1[2]. ML314 (2 μM) increases the number of NTR1 binding in U2OS cells[2]. In Vivo:ML314 (20 mg/kg, i.p., single dose) reduces locomotion in Dopamine Transporter knock-out mice[2]. ML314 (10-30 mg/kg, i.p., single dose) reduces hyperlocomotion and conditioned place preference in C57BL/6J mice exposed to Methamphetamine[2]. |
||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com